English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dear Sir,With great interest, we have read the updated ECCO consensus on the treatment of Crohn's disease.1 Being highly interested in research on the clinical use of thiopurines, we feel that several additional comments may give opportunity to a more balanced, evidence-based conclusion on the discarded use of 6-thioguanine as an alternative thiopurine.Firstly, the authors state that 6-thioguanine is the active metabolite of azathioprine and mercaptopurine. The drug 6-thioguanine has no pharmacological activity itself but needs to be metabolised to exert its immunomodulatory effects. The pharmacologically active anti-inflammatory metabolites of …

ECCO consensus: Evidence-based use of 6-thioguanine therapy in Crohn's disease?